Provided by Tiger Trade Technology Pte. Ltd.

BridgeBio Pharma, Inc.

76.59
-0.0100-0.01%
Post-market: 76.590.00000.00%19:41 EDT
Volume:2.06M
Turnover:157.22M
Market Cap:15.00B
PE:-21.46
High:77.24
Open:76.20
Low:75.02
Close:76.60
52wk High:93.42
52wk Low:48.78
Shares:195.81M
Float Shares:167.00M
Volume Ratio:1.42
T/O Rate:1.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5686
EPS(LYR):-3.7850
ROE:-1789.67%
ROA:-26.00%
PB:-5.96
PE(LYR):-20.24

Loading ...

BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder

THOMSON REUTERS
·
Aug 14

Omeros Q2 Yartemlea Net Revenue Jumps 190%

Reuters
·
Aug 13

BridgeBio Pharma is Maintained at Buy by Truist Securities

Dow Jones
·
Aug 13

Liquidia Q2 Revenue Jumps on Yutrepia Sales

Reuters
·
Aug 12

U.S. Research Roundup-Cardinal Health, Lumentum Holdings, Public Storage

Reuters
·
Aug 12

BridgeBio Oncology Therapeutics Beri Opsi Saham 65.350 Lembar Kepada Dua Karyawan Baru Dengan Harga Pelaksanaan USD 9,28

Reuters
·
Aug 12

Bridgebio Pharma Reports Inducement Grants Under NASDAQ Listing Rule

Reuters
·
Aug 12

BridgeBio Memberi 66.705 Unit Saham Terbatas Kepada 56 Karyawan Baru

Reuters
·
Aug 12

BridgeBio Pharma Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 12

BridgeBio Pharma Price Target Raised to $104.00/Share from $101.00 by B of a Securities

Dow Jones
·
Aug 12

BridgeBio Posted Q2 Revenue Beat, but Faces Higher Near-Term Launch Opex, Morgan Stanley Says

MT Newswires Live
·
Aug 11

Analysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Axsome Therapeutics (AXSM) and BridgeBio Pharma (BBIO)

TIPRANKS
·
Aug 11

BridgeBio Pharma, Inc. : Truist Securities Raises Target Price to $107 from $102

THOMSON REUTERS
·
Aug 11

BridgeBio Pharma : Bofa Global Research Raises Price Objective to $104.00 from $101.00

THOMSON REUTERS
·
Aug 11

BridgeBio price target lowered to $97 from $98 at Morgan Stanley

TIPRANKS
·
Aug 11

Legend Biotech Q2 Revenue Beats Estimates on Commercial Expansion

Reuters
·
Aug 11

C4 Therapeutics Q2 Revenue Beats Estimates, Helped by Roche Collaboration

Reuters
·
Aug 11

Wells Fargo Keeps Their Buy Rating on BridgeBio Pharma (BBIO)

TIPRANKS
·
Aug 11

Morgan Stanley Adjusts PT on BridgeBio Pharma to $97 From $98, Maintains Overweight Rating

MT Newswires Live
·
Aug 11

U.S. Research Roundup-Accendra Health, Celestica, Sionna Therapeutics

Reuters
·
Aug 11